Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry (ISACS CARDIONCO-PREDICT)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 10,000
- 试验地点
- 5
- 主要终点
- All causes mortality
研究概览
简要总结
This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years old or older
- •Capable of giving informed consent
- •Diagnosis of cancer scheduled for treatment according to treating physician's discretion
- •Life expectancy >1 year
- •For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs
排除标准
- •Age <18 years old
- •Not able to give informed consent
- •Life expectancy <1 year
- •Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's
结局指标
主要结局
All causes mortality
时间窗: For approximately a median of 3 years
Occurrence of all cause death
Cardiovascular mortality
时间窗: For approximately a median of 3 years
Occurrence of cardiovascular mortality
Cancer therapy-related cardiovascular toxicity
时间窗: For approximately a median of 3 years
Occurrence of cancer therapy-related cardiovascular toxicity
次要结局
未报告次要终点
研究者
Olivia Manfrini, MD
Professor
University of Bologna
